Baird Highlighgs NewLink Genetics' (NLNK) IDO Program Amid Algenpantucel-L Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Mizuho Securities Cuts Price Target on NewLink Genetics (NLNK) Following Failed IMPRESS Trial
May 10, 2016 1:22 PM EDTMizuho Securities maintained a Buy rating on NewLink Genetics (NASDAQ: NLNK), and cut the price target to $20.00 (from $52.00), following a failed IMPRESS Phase III trial.
Analyst Eric Criscuolo commented, "We reiterate our Buy rating but lower our PT from $52 to $20... More
NewLink Genetics (NLNK) Phase 3 Study of Algenpantucel-L Did Not Achieve Primary Endpoint
May 9, 2016 4:03 PM EDTNewLink Genetics Corporation (NASDAQ: NLNK) announced today results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer.
The IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint. Overall survival from time of randomization was 29.3 months for both groups combined. There was no statistically significant difference between the two groups. The... More
